Calpain inhibition by α-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography

Biochemistry

Volumn 45, Issue 24, 2006, Pages 7446-7452

  Cuerrier, D ^a   Moldoveanu, T ^a   Inoue, J ^b,c   Davies, P L ^a   Campbell, R L ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b SENJU PHARMACEUTICAL CO LTD   (Japan)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEXATION; CONFORMATIONS; DISEASES; ENZYME INHIBITION; ENZYME KINETICS; X RAY CRYSTALLOGRAPHY;

CALPAIN; CYCLIC HEMIACETAL INHIBITORS; KETOAMIDE; PROTEOLYSIS;

ENZYMES;

2 MORPHOLINOETHANESULFONIC ACID; ACETAL; ALDEHYDE; ALPHA KETOAMIDE; AMIDE; ANION; CALCIUM; CALPAIN; CYCLIC HEMIACETAL; CYSTEINE PROTEINASE; ENZYME INHIBITOR; GLUTAMIC ACID; HISTIDINE; HYDROXYL GROUP; MU CALPAIN; OXYGEN; SNJ 1715; SNJ 1945; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CALCIUM BINDING; CALCIUM HOMEOSTASIS; CATARACT; CORNEA PERMEABILITY; CRYSTAL STRUCTURE; DEGENERATION; DRUG DESIGN; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; ENZYME STRUCTURE; INJURY; ISCHEMIA; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CALPAIN; CATALYTIC DOMAIN; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; CYSTEINE; HYDROGEN BONDING; HYDROGEN-ION CONCENTRATION; ISOENZYMES; LEUPEPTINS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RATS; SEQUENCE HOMOLOGY, AMINO ACID; SOLUTIONS; WATER;

EID: 33745165901     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi060425j     Document Type: Article

References (38)

1. Goll, D. E., Thompson, V. F., Li, H., Wei, W., and Cong, J. (2003) The Calpain System, Physiol. Rev. 83, 731-801.
2. Wang, K. K., and Yuen, P. W. (1997) Development and therapeutic potential of calpain inhibitors, Adv. Pharmacol. 37, 117-152.
3. Carragher, N. O. (2006) Calpain inhibition: A therapeutic strategy targeting multiple disease states, Curr. Pharm. Des. 12, 615-638.
4. 2+ binding at two non-EF-hand sites, J. Biol. Chem. 279, 6106-6114.
5. Pal, G. P., Elce, J. S., and Jia, Z. (2001) Dissociation and aggregation of calpain in the presence of calcium, J. Biol. Chem. 276, 47233-47238.
6. 2+ switch aligns the active site of calpain, Cell 108, 649-660.
7. Neffe, A. T., and Abell, A. D. (2005) Developments in the design and synthesis of calpain inhibitors, Curr. Opin. Drug Discovery Dev. 8, 684-700.
8. Donkor, I. O., Han, J., and Zheng, X. (2004) Design, synthesis, molecular modeling studies, and calpain inhibitory activity of novel α-ketoamides incorporating polar residues at the P1′-position, J. Med. Chem. 47, 72-79.
9. Moldoveanu, T., Campbell, R. L., Guerrier, D., and Davies, P. L. (2004) Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site, J. Mol. Biol. 343, 1313-1326.
10. Moldoveanu, T., Hosfield, C. M., Lim, D., Jia, Z., and Davies, P. L. (2003) Calpain silencing by a reversible intrinsic mechanism, Nat. Struct. Biol. 10, 371-378.
11. Li, Q., Hanzlik, R. P., Weaver, R. F., and Schonbrunn, E. (2006) Molecular mode of action of a covalently inhibiting peptidomimetic on the human calpain protease core, Biochemistry 45, 701-708.
12. Nakamura, M., Miyashita, H., Yamaguchi, M., Shirasaki, Y., Nakamura, Y., and Inoue, J. (2003) Novel 6-hydroxy-3-morpholinones as cornea permeable calpain inhibitors, Bioorg. Med. Chem. 11, 5449-5460.
13. Schechter, I., and Berger, A. (1967) On the size of the active site in proteases. I. Papain, Biochem. Biophys. Res. Commun. 27, 157-162.
14. Nakamura, M., Yamaguchi, M., Sakai, O., and Inoue, J. (2003) Exploration of cornea permeable calpain inhibitors as anticataract agents, Bioorg. Med. Chem. 11, 1371-1379.
15. Auvin, S., Pignol, B., Navet, E., Pons, D., Marin, J. G., Bigg, D., and Chabrier, P. E. (2004) Novel dual inhibitors of calpain and lipid peroxidation, Bioorg. Med. Chem. Lett. 14, 3825-3828.
16. Li, Z., Patil, G. S., Golubski, Z. E., Hori, H., Tehrani, K., Foreman, J. E., Eveleth, D. D., Bartus, R. T., and Powers, J. C. (1993) Peptide α-keto ester, α-keto amide, and α-keto acid inhibitors of calpains and other cysteine proteases, J. Med. Chem. 36, 3472-3480.
17. Harbeson, S. L., Abelleira, S. M., Akiyama, A., Barrett, R., III, Carroll, R. M., Straub, J. A., Tkacz, J. N., Wu, C., and Musso, G. F. (1994) Stereospecific synthesis of peptidyl α-keto amides as inhibitors of calpain, J. Med. Chem. 37, 2918-2929.
18. Lescop, C., Herzner, H., Siendt, H., Bolliger, R., Hennebohle, M., Weyermann, P., Briguet, A., Courdier-Fruh, I., Erb, M., Foster, M., Meier, T., Magyar, J. P., and von Sprecher, A. (2005) Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy, Bioorg. Med. Chem. Lett. 15, 5176-5181.
19. Shirasaki, Y., Miyashita, H., Yamaguchi, M., Inoue, J., and Nakamura, M. (2005) Exploration of orally available calpain inhibitors: Peptidyl α-ketoamides containing an amphiphile at P3 site, Bioorg. Med. Chem. 13, 4473-4484.
20. Leslie, A. G. W. (1992) Recent changes to the MOSFLM package for processing film and image plate data, Joint CCP4 and ESF-EAMCB Newsletter on Protein Crystallography 26.
21. Potterton, E., McNicholas, S., Krissinel, E., Cowtan, K., and Noble, M. (2002) The CCP4 molecular-graphics project, Acta Crystallogr. D58, 1955-1957.
22. Vagin, A. T. (1997) MOLREP: An automated program for molecular replacement, J. Appl. Crystallogr. 30, 1022-1025.
23. Murshudov, G. N., Vagin, A. A., Lebedev, A., Wilson, K. S., and Dodson, E. J. (1999) Efficient anisotropic refinement of macromolecular structures using FFT, Acta Crystallogr. D55 (Part 1), 247-255.
24. McRee, D. E. (1999) XtalView/Xfit. A versatile program for manipulating atomic coordinates and electron density, J. Struct. Biol. 125, 156-165.
25. Schuttelkopf, A. W., and van Aalten, D. M. (2004) PRODRG: A tool for high-throughput crystallography of protein-ligand complexes, Acta Crystallogr. D60, 1355-1363.
26. DeLano, W. L. (2003) PvMol, DeLano Scientific LLC, San Carlos, CA.
27. Barrett, D. G., Boncek, V. M., Catalane, J. G., Deaton, D. N., Hassell, A. M., Jurgensen, C. H., Long, S. T., McFadyen, R. B., Miller, A. B., Miller, L. R., Payne, J. A., Ray, J. A., Samano, V., Shewchuk, L. M., Tavares, F. X., Wells-Knecht, K. J., Willard, D. H., Jr., Wright, L. L., and Zhou, H. Q. (2005) P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K, Bioorg. Med. Chem. Lett. 15, 3540-3546.
28. Barrett, D. G., Catalane, J. G., Deaton, D. N., Hassell, A. M., Long, S. T., Miller, A. B., Miller, L. R., Shewchuk, L. M., Wells-Knecht, K. J., Willard, D. H., Jr., and Wright, L. L. (2004) Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1′, P1, and/or P3 substitutions, Bioorg. Med. Chem. Lett. 14, 4897-4902.
29. Barbato, G., Cicero, D. O., Cordier, F., Narjes, F., Gerlach, B., Sambucini, S., Grzesiek, S., Matassa, V. G., De Francesco, R., and Bazzo, R. (2000) Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain, EMBO J. 19, 1195-1206.
30. Liu, Y., Stoll, V. S., Richardson, P. L., Saldivar, A., Klaus, J. L., Molla, A., Kohlbrenner, W., and Kati, W. M. (2004) Hepatitis C NS3 protease inhibition by peptidyl-α-ketoamide inhibitors: Kinetic mechanism and structure, Arch. Biochem. Biophys. 421, 207-216.
31. Krishnan, R., Tulinsky, A., Vlasuk, G. P., Pearson, D., Vallar, P., Bergum, P., Brunck, T. K., and Ripka, W. C. (1996) Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an α-keto-amide transition-state mimetic, Protein Sci. 5, 422-433.
32. Maryanoff, B. E., Qiu, X., Padmanabhan, K. P., Tulinsky, A., Almond, H. R., Jr., Andrade-Gordon, P., Greco, M. N., Kauffman, J. A., Nicolaou, K. C., Liu, A., et al. (1993) Molecular basis for the inhibition of human α-thrombin by the macrocyclic peptide cyclotheonamide A, Proc. Natl. Acad. Sci. U.S.A. 90, 8048-8052.
33. Walter, J., and Bode, W. (1983) The X-ray crystal structure analysis of the refined complex formed by bovine trypsin and p-amidinophenylpyruvate at 1.4 Å resolution, Hoppe-Seyler's Z. Physiol. Chem. 364, 949-959.
34. Chen, Z., Li, Y., Mulichak, A. M., Lewis, S. D., and Shafer, J. A. (1995) Crystal structure of human α-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 Å resolution, Arch. Biochem. Biophys. 322, 198-203.
35. Chen, Y., Leonetti, F., Greenbaum, D. C., Lecaille, F., Bogyo, M., Bromme, D., Ellman, J. A., and Craik, C. S. (2006) Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities, J. Biol. Chem. 281, 12824-12832.
36. Cuerrier, D., Moldoveanu, T., and Davies, P. L. (2005) Determination of peptide substrate specificity for μ-calpain by a peptide library-based approach: The importance of primed side interactions, J. Biol. Chem. 280, 40632-40641.
37. Bartus, R. T., Hayward, N. J., Elliott, P. J., Sawyer, S. D., Baker, K. L., Dean, R. L., Akiyama, A., Straub, J. A., Harbeson, S. L., Li, Z., et al. (1994) Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration, Stroke 25, 2265-2270.
38. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Res. 22, 4673-4680.